Roche Receives FDA Accelerated Approval for Lunsumio VELO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
FDA Approval: Roche's Lunsumio VELO (mosunetuzumab) has received FDA approval as a subcutaneous treatment for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, based on phase I/II study results.
Treatment Efficiency: The new formulation allows treatment to be administered in just one minute, significantly reducing the time patients spend in the clinic and catering to their individual needs and preferences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
